NasdaqGS - Delayed Quote • USD
Enanta Pharmaceuticals, Inc. (ENTA)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | -1.33 | -1.23 | -5.09 | -4.67 |
| Low Estimate | -1.63 | -1.65 | -6.55 | -6.69 |
| High Estimate | -1.11 | -0.91 | -4.35 | -3.35 |
| Year Ago EPS | -1.79 | -1.86 | -6.38 | -5.09 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 6 | 7 |
| Avg. Estimate | 16.52M | 16.88M | 67.82M | 74.92M |
| Low Estimate | 14M | 14M | 59M | 50M |
| High Estimate | 18M | 20M | 72.6M | 111.94M |
| Year Ago Sales | -- | -- | 79.2M | 67.82M |
| Sales Growth (year/est) | -- | -- | -14.40% | 10.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.98 | -2.34 | -2.15 | -1.19 |
| EPS Actual | -1.79 | -1.86 | -1.33 | -1.58 |
| Difference | 0.19 | 0.48 | 0.82 | -0.39 |
| Surprise % | 9.60% | 20.50% | 38.10% | -32.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.33 | -1.23 | -5.09 | -4.67 |
| 7 Days Ago | -1.33 | -1.23 | -5.09 | -4.67 |
| 30 Days Ago | -1.33 | -1.23 | -5.09 | -4.67 |
| 60 Days Ago | -1.35 | -1.22 | -5.13 | -4.82 |
| 90 Days Ago | -1.24 | -1.12 | -5.15 | -4.71 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ENTA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.70% | -- | -- | 0.30% |
| Next Qtr. | 33.90% | -- | -- | 9.80% |
| Current Year | 20.20% | -- | -- | 4.50% |
| Next Year | 8.30% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.06% |
| Past 5 Years (per annum) | -10.60% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | JP Morgan: Underweight to Underweight | 2/8/2024 |
| Maintains | Oppenheimer: Perform to Perform | 11/22/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/21/2023 |
| Maintains | JMP Securities: Outperform to Outperform | 11/21/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 10/23/2023 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 10/2/2023 |
Related Tickers
ITOS iTeos Therapeutics, Inc.
10.99
+1.85%
AGIO Agios Pharmaceuticals, Inc.
31.81
+5.30%
BCAB BioAtla, Inc.
2.2400
+2.75%
PTCT PTC Therapeutics, Inc.
25.41
-2.16%
MGNX MacroGenics, Inc.
16.23
+5.32%
STRO Sutro Biopharma, Inc.
3.7200
-1.33%
XENE Xenon Pharmaceuticals Inc.
41.09
+2.70%
BPMC Blueprint Medicines Corporation
92.29
+1.85%
IKNA Ikena Oncology, Inc.
1.3500
+3.85%
THRD Third Harmonic Bio, Inc.
11.05
-5.15%